Regenxbio Inc Cmn (RGNX) 15.95 $RGNX
REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV(R) Gene Therapy in Neurodegenerative Diseases
GlobeNewswire - Tue Sep 13, 6:00AM CDT
-- Preclinical study of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) demonstrates disease correction from a single administration of NAV AAV9 in a canine model; expected to help establish minimum effective dose in humans
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in Global Healthcare Conferences
GlobeNewswire - Wed Sep 07, 3:01PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
RGNX: 15.95 (+0.80), MS: 31.70 (+0.10)
Daniel Tasse Appointed to REGENXBIO Board of Directors
GlobeNewswire - Tue Aug 16, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel Tasse to its board of directors, effective August 15, 2016.
RGNX: 15.95 (+0.80)
REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Tue Aug 09, 7:00AM CDT
-- On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016
RGNX: 15.95 (+0.80)
Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
GlobeNewswire - Mon Aug 08, 3:01PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016.
RGNX: 15.95 (+0.80)
FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)
GlobeNewswire - Tue Aug 02, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO's investigational gene therapy product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II).
RGNX: 15.95 (+0.80)
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Mon Aug 01, 3:02PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that it will host a conference call on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2016 and recent operational highlights.
RGNX: 15.95 (+0.80)
REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
GlobeNewswire - Mon May 16, 6:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV Technology Platform for the treatment of two rare genetic vision disorders. The NAV Technology Platform is an AAV gene delivery platform consisting of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
RGNX: 15.95 (+0.80)
REGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Thu May 05, 7:01AM CDT
-- On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in May Investor Conferences
GlobeNewswire - Tue May 03, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that President and CEO Kenneth T. Mills will participate in the following May investor conferences.
RGNX: 15.95 (+0.80)
Preclinical Data from REGENXBIO's RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
GlobeNewswire - Tue Apr 19, 7:00AM CDT
-- High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degeneration
RGNX: 15.95 (+0.80)
REGENXBIO Provides Year-End 2015 Corporate Update
GlobeNewswire - Thu Jan 07, 7:00AM CST
-- Company begins 2016 in strong financial position, on track to advance multiple lead gene therapy product candidate programs into clinic
RGNX: 15.95 (+0.80)
FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
GlobeNewswire - Wed Dec 30, 7:00AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-111, the Company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I (MPS I).
RGNX: 15.95 (+0.80)
REGENXBIO Added to Russell 2000(R) Index
GlobeNewswire - Fri Dec 18, 3:15PM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced the company was added to the Russell 2000(R) Index as part of Russell Investments' quarterly addition of initial public offering companies. REGENXBIO joined the index after the NASDAQ market closed on December 18, 2015.
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire - Tue Dec 01, 8:12AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that President and CEO Kenneth T. Mills will participate in the following upcoming investor and scientific conferences:
RGNX: 15.95 (+0.80)
Regenxbio reports 3Q loss
Automated Insights - Thu Nov 05, 9:07AM CST
ROCKVILLE, Md. (AP) _ Regenxbio Inc. (RGNX) on Thursday reported a loss of $7.3 million in its third quarter.
RGNX: 15.95 (+0.80)
REGENXBIO Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 05, 7:02AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today reported recent operational highlights and financial results for the quarter ended September 30, 2015.
RGNX: 15.95 (+0.80)
Dr. David C. Stump Appointed to REGENXBIO Board of Directors
GlobeNewswire - Thu Oct 15, 7:01AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board of directors.
RGNX: 15.95 (+0.80)
FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
GlobeNewswire - Thu Oct 01, 4:05PM CDT
REGENXBIO Inc. (REGENXBIO) (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REGENXBIO's investigational gene therapy product candidate RGX-111 for the treatment of mucopolysaccharidosis Type I (MPS I).
RGNX: 15.95 (+0.80)
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Sep 22, 3:02PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to REGENXBIO were approximately $159.4 million, before underwriting discounts and estimated offering expenses.
RGNX: 15.95 (+0.80), MS: 31.70 (+0.10)
REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV(R) Gene Therapy in Neurodegenerative Diseases
GlobeNewswire - Tue Sep 13, 6:00AM CDT
-- Preclinical study of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I) demonstrates disease correction from a single administration of NAV AAV9 in a canine model; expected to help establish minimum effective dose in humans
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in Global Healthcare Conferences
GlobeNewswire - Wed Sep 07, 3:01PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 in New York.
RGNX: 15.95 (+0.80), MS: 31.70 (+0.10)
Daniel Tasse Appointed to REGENXBIO Board of Directors
GlobeNewswire - Tue Aug 16, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel Tasse to its board of directors, effective August 15, 2016.
RGNX: 15.95 (+0.80)
REGENXBIO Reports Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Tue Aug 09, 7:00AM CDT
-- On track to enroll first patients for Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia in the second half of 2016
RGNX: 15.95 (+0.80)
Daniel J. Abdun-Nabi Appointed to REGENXBIO Board of Directors
GlobeNewswire - Mon Aug 08, 3:01PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016.
RGNX: 15.95 (+0.80)
FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)
GlobeNewswire - Tue Aug 02, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-121, REGENXBIO's investigational gene therapy product candidate for the treatment of Mucopolysaccharidosis Type II (MPS II).
RGNX: 15.95 (+0.80)
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Mon Aug 01, 3:02PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that it will host a conference call on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2016 and recent operational highlights.
RGNX: 15.95 (+0.80)
REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
GlobeNewswire - Mon May 16, 6:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV Technology Platform for the treatment of two rare genetic vision disorders. The NAV Technology Platform is an AAV gene delivery platform consisting of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
RGNX: 15.95 (+0.80)
REGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights
GlobeNewswire - Thu May 05, 7:01AM CDT
-- On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in May Investor Conferences
GlobeNewswire - Tue May 03, 7:00AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV(R) Technology Platform, today announced that President and CEO Kenneth T. Mills will participate in the following May investor conferences.
RGNX: 15.95 (+0.80)
Preclinical Data from REGENXBIO's RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
GlobeNewswire - Tue Apr 19, 7:00AM CDT
-- High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degeneration
RGNX: 15.95 (+0.80)
REGENXBIO Provides Year-End 2015 Corporate Update
GlobeNewswire - Thu Jan 07, 7:00AM CST
-- Company begins 2016 in strong financial position, on track to advance multiple lead gene therapy product candidate programs into clinic
RGNX: 15.95 (+0.80)
FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
GlobeNewswire - Wed Dec 30, 7:00AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to RGX-111, the Company's investigational gene therapy product candidate for the treatment of mucopolysaccharidosis Type I (MPS I).
RGNX: 15.95 (+0.80)
REGENXBIO Added to Russell 2000(R) Index
GlobeNewswire - Fri Dec 18, 3:15PM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced the company was added to the Russell 2000(R) Index as part of Russell Investments' quarterly addition of initial public offering companies. REGENXBIO joined the index after the NASDAQ market closed on December 18, 2015.
RGNX: 15.95 (+0.80)
REGENXBIO to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire - Tue Dec 01, 8:12AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that President and CEO Kenneth T. Mills will participate in the following upcoming investor and scientific conferences:
RGNX: 15.95 (+0.80)
Regenxbio reports 3Q loss
Automated Insights - Thu Nov 05, 9:07AM CST
ROCKVILLE, Md. (AP) _ Regenxbio Inc. (RGNX) on Thursday reported a loss of $7.3 million in its third quarter.
RGNX: 15.95 (+0.80)
REGENXBIO Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 05, 7:02AM CST
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today reported recent operational highlights and financial results for the quarter ended September 30, 2015.
RGNX: 15.95 (+0.80)
Dr. David C. Stump Appointed to REGENXBIO Board of Directors
GlobeNewswire - Thu Oct 15, 7:01AM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board of directors.
RGNX: 15.95 (+0.80)
FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)
GlobeNewswire - Thu Oct 01, 4:05PM CDT
REGENXBIO Inc. (REGENXBIO) (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REGENXBIO's investigational gene therapy product candidate RGX-111 for the treatment of mucopolysaccharidosis Type I (MPS I).
RGNX: 15.95 (+0.80)
REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Sep 22, 3:02PM CDT
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to REGENXBIO were approximately $159.4 million, before underwriting discounts and estimated offering expenses.
RGNX: 15.95 (+0.80), MS: 31.70 (+0.10)
